Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Azerbaijan (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Kazakhstan (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Uzbekistan (1)
STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG
STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.
STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…
Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…
STADA continues to advance its strategic reorientation.
STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.
STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…
STADA is systematically pushing ahead with the new strategy announced in March.
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology
At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…
The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…
STADA is advancing the internationalization of its OTC brand business.
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …
Frank Staud assumes overall responsibility for the STADA brand and communications
Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman
STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts
Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding …
STADA takeover offer by Bain Capital and Cinven successful
Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached
STADA shows good operational development in first six months of 2017
Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven
Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG
STADA supports renewed improved takeover offer announced by Bain Capital and Cinven
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions
Changes in the Executive Board of STADA Arzneimittel AG
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Ca…
STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven
To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share
STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised
STADA postpones press and analyst conference on full year figures 2016
to March 29, 2017
STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
Changes in the Executive Board of STADA Arzneimittel AG
STADA acquires UK branded product company Natures Aid
STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year …
STADA lays the groundwork for sustainable growth
STADA: Leslie Iltgen is the new Vice President Investor Relations
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board
STADA: Excellent business development in the first six months of 2016 – reported and adjusted key earnings figures significantly above previ…
STADA approves growth targets for 2019: adjusted Group sales Euro 2.6 billion, adjusted EBITDA Euro 510 million and adjusted net income Euro…
STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published
STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 mill…
STADA with dynamic sales growth in the first half of 2013
STADA: Executive Board gives a positive summary of 2012 at Annual General Meeting and adheres to the positive outlook till 2014 – Supervisor…
STADA: Successful placement of a corporate bond in the amount of Euro 350 million
STADA: Good start in the first quarter of 2013 – organic growth accelerated
With "STADA Diagnostik" STADA is entering the personalized drug therapy business
STADA to establish logistics and distribution center in Dubai
STADA: Successful financial year 2012 – Adjusted EBITDA at record level – Dividend to increase by over 35 percent – Positive outlook to 2014…
AOK 11 tender round: STADA takes top active ingredients
STADA's subsidiary Eurogenerics increases profitability with new distribution agreement in Belgium
STADA wins discount agreement tenders with Germany’s three largest public health insurers
STADA scholarships support the advancement of Charité top performers